MD Anderson and KKR-backed Replay form new product company Syena to pioneer first-in-class TCR NK cell therapy

“NK cells play a pivotal role in anticancer immunity and, following the successes of CAR T cell therapy and the potential for CAR NK therapies, TCR NK cells are positioned to be a next-generation agent for cancer therapy,” Rezvani said. “We believe that the TCR NK cell approach will allow targeting of a broad range of tumor antigens, including cancer-specific neoantigens, and could pave the way for potentially safe and efficacious ‘off-the-shelf’ cell therapies for hematological malignancies and solid tumors.”